Upregulation of fatty acid synthase (FASN), the key metabolic multi-enzyme that is responsible for the terminal catalytic step in FA synthesis, represents a nearly-universal phenotypic alteration ...

The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne vulgaris. The trial was conducted by ...

About BJT-188 BJT-188 is a preclinical, liver-targeted fatty acid synthase (FASN) inhibitor currently under investigation by Bluejay Therapeutics for the treatment of metabolic dysfunction ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) saw its stock soar 20% after unveiling encouraging Phase 3 trial results for its acne ...

Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I am bullish on the company.

April 22, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to ...

Keemun black tea extract contains potent fatty acid synthase inhibitors and reduces food intake and body weight of rats via oral administration, Journal of Enzyme Inhibition and Medicinal ...

RAD101 is the Company's novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that ...

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

Sagimet Biosciences (NASDAQ: SGMT) stock surged 38% on premarket news of positive Phase 3 trial results for its acne therapy denifanstat in China. Read more here.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...